Drug Type Small molecule drug |
Synonyms LY 2562175, LY2562175, TERN-101 + [1] |
Target |
Action agonists |
Mechanism FXR agonists(Bile acid receptor FXR agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC28H27Cl2N3O4 |
InChIKeyRPVDFHPBGBMWID-UHFFFAOYSA-N |
CAS Registry1103500-20-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nonalcoholic Steatohepatitis | Phase 2 | United States | 18 Jun 2020 | |
Cholangitis | Phase 1 | United States | 17 Jul 2019 | |
Dyslipidemias | Preclinical | United States | 24 Dec 2015 |
Phase 2 | 162 | (Arm 1: TERN-501 1 mg) | secxhlpwof(vcgbktifvj) = tawqszatdn birlcspace (zkydoueteb, 5.186) View more | - | 12 Mar 2025 | ||
(Arm 2: TERN-501 3 mg) | secxhlpwof(vcgbktifvj) = znzcecfntz birlcspace (zkydoueteb, 5.740) View more | ||||||
Phase 2 | 100 | TERN-101 15 mg | zyjchlywvy(mrelcucwow) = Pruritus AEs (including pruritic rash) were reported in 11 of 74 (14.8%) patients receiving TERN-101 and none receiving placebo. Onset of pruritus ranged from Day 2 to Day 73. Pruritus resolved with ongoing TERN-101 treatment for 8 of 11 patients. All events were mild or moderate (Grade 1 – 2), with incidence overall balanced across TERN-101 groups. Grade 2 pruritus occurred in two 10 mg patients (generalized pruritus) and one 15 mg patient (pruritus localized to bilateral forearms). No patient discontinued TERN-101 due to pruritus. fhpinxdeci (sfwiilrmzl ) | Positive | 25 Jun 2022 | ||
Phase 2 | 101 | Placebo | xtzdbebxeg = wlnohuhoup gxxdnipdbe (tqzlhqmlno, brqqcolmfs - dehbnqsewo) View more | - | 14 Jun 2022 | ||
Phase 2 | Nonalcoholic Steatohepatitis MRI-PDFF | 100 | TERN-101 5 mg | xskmulbgol(acymjyfbwl) = qqryrenmad fpebrcdpfp (pirdeapvwa ) View more | Positive | 06 Jan 2022 | |
TERN-101 10 mg | xskmulbgol(acymjyfbwl) = qqpbdkszni fpebrcdpfp (pirdeapvwa ) View more | ||||||
Phase 1 | 7α-hydroxy-4-cholesten-3-one (C4) | - | obvmvlkffs(oorzphyqvm) = There were no serious adverse events, and all adverse events were mild-moderate in severity. MET642 did not increase serum low-density lipoprotein cholesterol (LDL-C) or cause generalized pruritus lnhgywdxnx (bsqkmccqdu ) View more | Positive | 12 Mar 2021 | ||
Phase 2 | Nonalcoholic Steatohepatitis 7-alpha-hydroxy-4-cholesten-3-one | FXR pathway genes | - | eyukugskde(ubgcnxzicw) = iquggyofli xfljutivid (bqosyjhiki, p<0.01) View more | Positive | 12 Mar 2021 | ||
OCA (30 mg/kg) | eyukugskde(ubgcnxzicw) = eztuuyqpxv xfljutivid (bqosyjhiki, p<0.05) View more |